

Original Research Article

Laser-Assisted Opening of Gold Micro Shunt's Windows in Glaucoma: Efficacy and Safety

Abstract

Objective: To determine the intraocular pressure-lowering effect and safety of opening the Gold Micro Shunt Plus' (GMS+) windows with a titanium-sapphire laser.

Design: Retrospective case series

Participants: The charts of 5 patients were reviewed. Diagnoses included primary open-angle glaucoma (n=3), aphakic glaucoma (n=1) and neovascular glaucoma (n=1). There were 4 males and 1 female, aged between 56 and 81 (mean age 70 ± 11). Four of the patients were Caucasian and one was Hispanic. They had undergone a mean of 2 ± 1.6 surgeries (range: 0-4) before GMS implantation.

Methods: The GMS+ was implanted in five consecutive patients between December 2008 and March 2010 in two hospitals. IOP and number of glaucoma medications were recorded before and after the implantation of the GMS, as well as before and after the opening of the GMS' windows with a titanium-sapphire (Ti-Sap) laser. Patients were assessed for complications arising from implanting the GMS and opening its windows.

Results: The GMS+ had 8 closed windows and one open flow port upon implantation. Four of these windows were opened in all five patients. Mean IOP before GMS implantation was 29.9 ± 8.5 mmHg and it was 18.6 ± 6.5 mmHg after implantation. Hence, implantation of the GMS was associated with an average decrease in IOP of 11.3 ± 4.2 mmHg or 37.0% ($p=0.076$). The mean IOP before window-opening was 24.9 ± 5.8 mmHg and after window opening, it was 17.6 ± 5.7 mmHg. The IOP thus dropped 7.3 ± 4.6 mmHg or 29.3% ($p=0.055$) on average after opening the GMS' windows. The windows were opened an average 6.4 ± 4.5 months after GMS implantation. Long-term IOP at follow-ups remained lower than pre-GMS levels in all patients. The IOP reduction post window opening lasted throughout follow-up, i.e. from 17 to 42 months (average 30 ± 10 months). The number of glaucoma drops for each patient did not decrease after opening the GMS' windows. One patient developed transitory cystoid macular edema after GMS implantation that resolved with a course of NSAID drops. No complications arose from the opening of the GMS' windows.

Conclusions: In our small case series, opening the GMS' windows was safe and was associated with a substantial and sustained reduction in IOP.

Introduction

Several surgical treatments exist for glaucoma. Conventional surgical approaches such as trabeculectomy and glaucoma drainage devices connect the anterior chamber (AC) to the subconjunctival space, and form a filtering bleb. These procedures have been effective in many cases but are associated with potential complications, including bleb leaks with hypotony, tube erosions and endophthalmitis¹.

A surgical technique that allows drainage of aqueous humour from the anterior chamber to the suprachoroidal space, while avoiding the complications linked to bleb formation, has been previously described². The Gold Micro Shunt (GMS) (SOLX Inc, Waltham, MA) is a newer suprachoroidal shunt that also lowers IOP without bleb formation³ and has been proven to reduce IOP from 32.6 to 45.3%^{4,5}.

It has been noted that both traditional shunts as well as suprachoroidal shunts, may fail due to marked encapsulation secondary to the high degree of scarring.^{1,2,6} This may be due to the initial high flow through the implant, which induces fibrosis⁷. It is thus hypothesized that using a shunt in which the windows are initially closed like the GMS, and opening the windows after a few months, may lead to a slower egress of fluid and thus decrease the incidence of fibrosis and the pressure elevations associated with it.

The goal of this study was to determine the IOP-lowering effect and safety of opening the GMS' windows.

Methods

Shunt Design:

The Gold Micro Shunt Plus is a sterile, flat drainage device made from 24-K medical-grade (99.95%) gold. The device used in this study is approximately 6 mm long, 3 mm wide and 80 μ m thick. The proximal or "head" end of the device has 8 closed ports and 1 open flow port which directs aqueous flow into the device. The 8 closed ports have a width of 100 micron and a height of 60 micron. The 1 open port is 50 micron wide by 60 micron height. The distal or "tail" end terminates in the suprachoroidal space with openings that allow aqueous to flow out through that end of the device. Larger reinforced openings aligned along the centerline of the device are designed to help in positioning the device. A protective, sterile insertion tool is supplied to aid with handling and insertion of the implant.

The GMS+ used in this study had eight closed windows. Four of these windows were opened all at once in all our patients when IOP was above target. The windows were opened with a Latina lens and Ti-Sap laser after an average of 6.4 $\pm$ 4.5 months [range: 1-9].

Clinical Study:

All cases that have undergone GMS insertion between December 2008 and March 2010 were included in this study. These five cases were retrospectively

analysed from July to September 2012. The main outcomes were the complications and IOP associated with opening the GMS windows. The study was accepted by the IRB of Maisonneuve-Rosemont Hospital, and followed the tenets of the Helsinki Agreement. All patients signed an informed consent form to participate in the study.

After an initial fornix based conjunctival flap was made, a square-shaped scleral flap measuring 3.5 x 3.5 mm was dissected. Mitomycin C (500 mcg per mL) was then applied to the scleral bed for one minute, and washed with BSS. A full thickness incision into the suprachoroidal space was made posteriorly, and then the anterior chamber was penetrated using a 2.75 keratome and enlarged. The GMS was implanted into the AC and the tail end in the suprachoroidal space. The superficial scleral flap was closed with a single 10.0 Nylon suture and the conjunctiva was closed with a 10.0 Vicryl suture using a modified Wise technique.

IOP was monitored regularly and if it was judged to be above target, the patient was scheduled for laser assisted window opening. The windows were opened after an average of 6.4 ± 4.5 months [range: 1-9]. The Titanium-Sapphire laser procedure was performed with a 200 micron spot size, 790 nm wavelength, and 7 msec exposure time using 1-2 shots per window of 30-40mJ. Topical Nepafenac (Nevanac, Alcon) drops were applied qid for four days after window ablation. The IOP (using a Goldmann tonometer) and number of glaucoma

medications were recorded immediately after laser, as well as one, three, six and twelve months after laser. Follow-up was organized every 4-6 months thereafter.

Statistical analysis:

The paired student t-test was used to calculate differences between pre- and post-GMS implantation IOP, as well as between pre- and post-window opening IOP. The Friedman p-value was calculated to compare the pre-GMS and last follow-up's IOP (see Figure 1), as an average of the five patients. A paired student t-test was also used to compare the number of glaucoma drops pre-GMS and at the most recent follow-up.

Results

Among the research subjects, there were 4 males and 1 female, with a mean age of 70 ± 11 year (range: 56-81). Three patients had primary open-angle glaucoma, one had aphakic glaucoma and one had neovascular glaucoma (**Table 1**). Four of the patients were Caucasian and one was Hispanic. They had undergone a mean of 2 ± 1.6 surgeries (range: 0-4) before GMS implantation. Three patients were pseudophakic, one was phakic and one was aphakic. In terms of previous glaucoma surgeries, three had undergone a trabeculectomy, two had undergone a laser trabeculoplasty and three had other glaucoma drainage devices.

The GMS had 8 closed windows and one open port upon implantation. Four of these windows were opened in all five patients. Average follow-up post GMS implantation was 30 ± 10 months.

140 Mean IOP before GMS implantation was 29.9 ± 8.5 mmHg and it was 18.6 ± 6.5
141 mmHg after implantation. Hence, implantation of the GMS was associated with
142 an average decrease in IOP of 11.3 ± 4.2 mmHg or 37.0% ($p=0.076$) (**Figure 1**).
143 The mean IOP before window-opening was 24.9 ± 5.8 mmHg and after window
144 opening, it was 17.6 ± 5.7 mmHg. The IOP thus dropped 7.3 ± 4.6 mmHg or
145 29.3% ($p=0.055$) on average after opening the GMS' windows (**Figure 1**). The
146 windows were opened an average 6.4 ± 4.5 months after GMS implantation. IOP
147 dropped 2.3 to 10.7% per window opened (mean 7.3%). Mean IOP at the last
148 follow-up was 18.4 ± 5.0 mmHg. Mean IOP reduction from pre-GMS to most
149 recent follow-up is 38.5%.

150 Long-term IOP at follow-ups remained lower than pre-GMS levels in all patients.
151 The IOP reduction post window opening lasted throughout follow-up, i.e. from 17
152 to 42 months (average 30 months).

153 The mean number of glaucoma drops was 2.6 ± 1.1 before GMS implantation
154 and 2.8 ± 1.1 afterwards. The pre-operative glaucoma drops were continued as
155 is after GMS implantation. Before opening the GMS' windows, the average
156 number of drops was 2.4 ± 0.9 and remained identical after opening the GMS'
157 windows (**Figure 2**). At the last follow-up, the average number of drops was $3.0 \pm$
158 0.7 ($p=0.26$, student t-test). One patient developed transitory cystoid macular
159 edema after GMS implantation that resolved with a course of Nepafenac
160 (Nevanac, Alcon) drops four times per day during a month. No complication
161 arose from opening of the GMS' windows.

Discussion

Molteno et al suggested that a rapid egress of aqueous humour from the anterior chamber into the subconjunctival space after implanting a glaucoma shunt can lead to conjunctival fibrosis⁷ and subsequent elevation in IOP. In order to minimize this effect, the current study analyzed the effect of implanting a GMS with 8 closed windows and only one small open channel to limit the initial egress of fluid from the anterior chamber to the suprachoroidal space. In opening the GMS' windows a few months after implantation to decrease IOP further, it was postulated that this would limit the conjunctival fibrosis and subsequent IOP spikes described by Molteno et al.

In this study, IOP decreased significantly after GMS implantation. There was still a moderate increase in IOP post-operatively, suggesting some healing response, however after opening the GMS' windows, the IOP decreased below the post-implantation level. In our small case series, this lowered IOP was sustained until the end of our patients' follow-up, without further pressure elevations. This is in contrast to a recent study that noted failure in almost all of their GMS cases⁸.

This series is different not only in shunt design but in the use of MMC in our series as well. We postulate that the use of MMC diminishes fibrosis around the GMS and helps prevent late pressure spikes seen in other studies. Another recent study found that failure was associated with inflammatory cells in the suprachoroidal space⁹. In that study, a different shunt design was used and no MMC was deployed.

184 In this series, GMS implantation was safe, with no post-operative blebs. It has a
185 favorable complication profile when compared to trabeculectomy and other bleb-
186 requiring procedures. No complications linked to opening the GMS' windows
187 were noted in this series, and no gold particles were seen within the eye at any of
188 the post laser visits. In this small cohort of patients with high IOP on maximum
189 medical therapy, the IOP reduction associated with GMS implantation and
190 window opening was sustained throughout the post-operative period, but the
191 average number of glaucoma drops remained largely constant throughout follow-
192 up. It has to be noted that the pre- vs post-GMS implantation ($p=0.07$) and pre-
193 vs post-window opening ($p=0.055$) IOP reduction was not statistically significant.
194 However, we consider that the IOP reduction was definitely significant from a
195 clinical standpoint. The small sample size accounts for the lack of statistical
196 significance in this study.

197 One of the current study's strengths is its follow-up duration (averaging 30
198 months and up to 42 months in one patient). However, the obvious limitation is its
199 small sample size. Larger cohorts of patients with suprachoroidal implants that
200 initially limit flow, used concomitantly with anti-fibrotics are needed. Future shunt
201 designs may consider using a similar strategy that limit initial aqueous outflow,
202 and permit future increase with office based procedures such as laser-assisted
203 window opening, once the post-operative inflammation has subsided. Similar
204 laser procedures have been used for suture lysis in trabeculectomies and
205 removal of the tube ligature in Baerveldt drainage devices. In summary, in our
206 small case series, opening the GMS' windows was safe and was associated with

a substantial and sustained reduction in IOP. The GMS is thus an interesting alternative to trabeculectomy and other conventional surgical approaches in the treatment of patients with refractory glaucoma.

Bibliography:

1. Gedde SJ. Postoperative complications in the Tube Versus Trabeculectomy(TVT) study during five years of follow-up. Am J Ophthalmol. 2012 May;153(5):804-814
2. Jordan JF et al. A novel approach to suprachoroidal drainage for the surgical treatment of intractable glaucoma. J Glaucoma. 2006, 15:200-205
3. Mastropasqua et al. In Vivo Analysis of Conjunctiva in GMS Implantation for Glaucoma. Br J Ophthalmol 2010;94: 1592-96
4. Melamed et al. Efficacy and Safety of GMS Implantation in Supraciliary Space of Patients with Glaucoma. Arch Ophthalmol. 2009; 127:264-9
5. Figus et al. Supraciliary Shunt in Refractory Glaucoma. Br J Ophthalmol. 2012; 95: 1537-4
6. Agnifili et al. Histological Findings of Failed Gold Micro Shunts in POAG. Graefes Arch Oph. 2012 , 250(1): 143-9
7. Molteno et al. Otago Glaucoma Surgery Outcome Study: factors controlling capsule fibrosis around Molteno implants with histopathological correlation. Ophthalmol. Nov 2003. 110(11): 2198-206.
8. Hueber A, Roters S, Jordan JF, Konen W. Retrospective analysis of the success and safety of Gold Micro Shunt Implantation in glaucoma. BMC Ophthalmol. Jul 2013 18;13(1):35.
9. Rękas M, Pawlik B, Grala B et al, Clinical and morphological evaluation of gold micro shunt after unsuccessful surgical treatment of patients with primary open-angle glaucoma. Eye (Lond). Jul 2013.

	Table 1. Clinical characteristics of patients enrolled in the study				
	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5
Type of glaucoma	Neovascular	Aphakic	POAG	POAG	POAG
Lens status	Pseudophakic	Aphakic	Pseudophakic	Pseudophakic	Phakic
Pre-GMS filtration procedures	Trabeculectomy	Trabeculectomy Ahmed valve	Trabectome	None	Trabeculectomy with Express Shunt
T Max	34 OS	30 OD	34 OD	33 OD	26 OS
Central Corneal Thickness (in microns)	540 OS	620 OD	501 OD	535 OD	567 OS
Number of meds before GMS	4	3	1	3	2

Figure 1. IOP vs time, as an average of the five patients. IOP was measured before and after GMS implantation, before and after window opening and at the most recent follow-up.




Figure 2. Average number of drops versus time. The number of drops averaged between the 5 patients was measured before and after GMS implantation, before and after window opening and at the most recent follow-up.

